Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

J Clin Oncol. 2023 Feb 20;41(6):1323. doi: 10.1200/JCO.22.01759. Epub 2022 Nov 3.

Authors

Zachary R McCaw¹, Ethan B Ludmir¹, Lee-Jen Wei¹

Affiliation

¹ Zachary R. McCaw, PhD, Insitro, South San Francisco, CA; Ethan B. Ludmir, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Lee-Jen Wei, PhD, Harvard T.H. Chan School of Public Health, Boston, MA.

PMID: 36331242
DOI: 10.1200/JCO.22.01759

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Disease-Free Survival
Female
Humans
Paclitaxel / adverse effects
Treatment Outcome

Substances

Paclitaxel